Karantzoulis, Stella http://orcid.org/0000-0001-9707-517X
Heuer, Karli
Sparling, Nicole
Meltzer, Brian
Teynor, Megan
Funding for this research was provided by:
Alexion Pharmaceuticals
Article History
Received: 22 December 2023
Accepted: 27 February 2024
First Online: 4 April 2024
Declarations
:
: Megan Teynor and Brian Meltzer are employees of Alexion, AstraZeneca Rare Disease and may own stock/stock options in that company. Stella Karantzoulis, Karli Heuer, and Nicole Sparling are employees of IQVIA, which received professional service fees from Alexion, AstraZeneca Rare Disease for conducting the study.
: The concept elicitation interview portion of this study was approved by New England IRB (reference number 120190495) and the cognitive debriefing interview portion of the study was approved by WCG IRB (reference number 20212312). Informed consent was obtained from all participants prior to the start of interviews.